I'd imagine the patents are owned by the institutions the research is being conducted at and a Big Pharma will company will buy or license those patents after trials.
Startups are too small for shouldering the financial load of developing/testing/insurance/lab facilities/high end staff. Plus, Big Pharma has established distribution channels that would get a Type 1 like me my cure faster, which one may consider ethical territory.
